Xeris Biopharma Holdings (XERS): Can Shares Reach the $13 Target for +27.5% Upside?
Key Takeaways
- The central target used in this analysis is $13, the arithmetic mean of six verified, current analyst price targets, rounded from a calculated mean of $13.00.
- The latest verified market price is about $10.20, so reaching $13 would require a roughly 27.5% upside move.
- The analyst target range is unusually wide, from $8 (Piper Sandler) to $18 (Oppenheimer), reflecting sharply divergent views on the company's growth and pipeline.
- The strongest supporting factors are accelerating Recorlev sales, a return to profitability, and management's raised revenue guidance.
- The biggest risks are softness in Gvoke tied to Medicare policy changes, execution on a Phase 3 pipeline asset, and a valuation that has already re-rated significantly.
- Readers can find more on the ticker's Major News and Today's Price Move, along with its Forecast and Earnings pages.
- To monitor changing signals across thousands of stocks and ETFs, explore Trending AI Robots.
Analyst Price Targets and Consensus View
The $13 central target reflects six recent, individually attributed analyst price targets: Oppenheimer at $18, Leerink Partners at $16 (raised from $12 in September 2026), Barclays at $14 (raised from $12 in October 2026), Craig-Hallum at $12, H.C. Wainwright at $10, and Piper Sandler at $8. Averaging these produces a mean of exactly $13.00. That average conceals a very wide $8-to-$18 range. Bullish firms emphasize Recorlev's momentum and the company's move toward profitability, with Oppenheimer and Leerink carrying the highest targets. More cautious analysts, such as Piper Sandler's neutral $8, argue that the growth trajectory and pipeline execution still need to be proven. Notably, most revisions in late 2026 have been upward, but the dispersion means the "consensus" figure is not a strong signal of agreement. From what I see, this spread highlights how opinions can vary even among professionals covering the same XERS story.
Current Market Position and Path Toward the Target
With the stock near $10.20, reaching $13 implies a roughly 27.5% advance — a substantial move by most standards. The shares have already climbed about 30% year to date and touched a 52-week high near $11.42 in October 2026 before pulling back, so a portion of the upside has been priced in. Fundamentally, the path runs through continued Recorlev growth. The company reported revenue of about $335 million over the trailing twelve months, with management raising 2026 guidance to a range of roughly $380 million to $390 million. The company posted positive net income in the first quarter of 2026, a meaningful inflection for a business that had long been loss-making, and held roughly $122 million in cash. Sustained execution on these trends would be central to any move toward $13. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Could Support a Move Toward the Target
- Recorlev growth: The drug's revenue roughly doubled year over year and has become the company's best-selling product, anchoring the growth story.
- Profitability inflection: A swing to positive net income and non-GAAP profitability supports the higher-valuation case.
- Raised guidance: Management's upwardly revised 2026 revenue outlook signals confidence in demand.
- Pipeline optionality: XP-8121, a once-weekly subcutaneous levothyroxine in Phase 3, represents longer-term upside.
- Intellectual property and sentiment: A 2026 patent win related to Keveyis and generally constructive analyst revisions have supported the shares, and media reports have occasionally speculated about strategic interest in the company.
What Could Prevent the Target From Being Reached
- Gvoke headwinds: Revenue from Gvoke has lagged expectations due to Medicare policy changes, and a recovery is not assured.
- Execution risk: The Phase 3 XP-8121 program and continued Recorlev commercial ramp carry clinical and operational uncertainty.
- Valuation: With a forward P/E (price-to-earnings ratio) in the low-20s and a price-to-sales multiple near 5, the stock already embeds meaningful growth expectations; a slowdown could compress the multiple.
- Wide analyst dispersion: The gap between the $8 and $18 targets shows that even the sell side disagrees sharply about fair value.
- Macro and sector pressure: Rising rates or a rotation away from speculative small-cap biotech could weigh on sentiment regardless of fundamentals.
Technical Levels and Market Structure
The stock's 52-week range of roughly $5.25 to $11.42 frames the setup. The $11.40-to-$11.50 zone, marked by the October 2026 high, is the nearest meaningful resistance that must be cleared before $13 comes into view. On the downside, the $10 level and the 50-day moving average near $9 provide shorter-term reference points, while the March 2026 low near $5.25 represents a durable longer-term support level. The October 2026 pullback of about 6% in a single session illustrates the stock's volatility.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms may use different assumptions. Key items to watch include the quarterly earnings report scheduled for early November 2026, updates on Recorlev and Gvoke demand trends, any revisions to 2026 guidance, and clinical or regulatory developments for XP-8121. Changes in analyst targets — particularly whether the cautious low-end holders revise upward — will also matter for how the consensus evolves.
Final Assessment
The $13 target is the average of six current analyst price targets, not a single firm's view, and it sits roughly 27.5% above the latest price. Supporters point to Recorlev's accelerating growth, a return to profitability, and raised guidance; skeptics point to Gvoke softness, pipeline execution risk, and a valuation that has already re-rated. The $8-to-$18 analyst range underscores genuine disagreement. Reaching $13 would require clearing the stock's recent 52-week high and sustaining strong fundamentals, while a stumble in Recorlev or broader small-cap weakness could stall the advance. The upcoming earnings report and any analyst revisions are the next key signposts. I'm watching this closely as the next few quarters unfold.
AI Daily Buy/Sell Signals
In my own workflow, I frequently rely on AI Daily Buy/Sell Signals from Tickeron to track momentum shifts across a wide range of names. The tool applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals grounded in technical behavior and broader market conditions. For anyone following XERS or the biotech sector, these signals offer a practical way to stay aligned with evolving trends without constant manual review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
XERS in +7.95% Uptrend, growing for three consecutive days on October 20, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where XERS advanced for three days, in 220 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
XERS moved above its 50-day moving average on September 21, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for XERS crossed bullishly above the 50-day moving average on September 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 191 of 232 cases where XERS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Bearish Trend Analysis
The 10-day RSI Indicator for XERS moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator moved out of overbought territory. In 36 of the 45 cases, the stock moved lower in the following days. This puts the odds of a move lower at 80%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 52 of 65 cases where XERS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 80%.
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XERS as a result. In 64 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
The Moving Average Convergence Divergence Histogram (MACD) for XERS turned negative on October 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 34 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XERS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
XERS broke above its upper Bollinger Band on September 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: XERS's P/B Ratio (-191.049) is very low in comparison to the industry average of (9.032). P/E Ratio (-102.000) is within average values for comparable stocks, (-3.059). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (4.196) is also within normal values, averaging (178.797).
The Tickeron Profit vs. Risk Rating rating for this company is 27 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. XERS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of ready-to-use, liquid-stable injectables
Industry PharmaceuticalsGeneric
Advertisement